Patent application number | Description | Published |
20090103926 | SYSTEMS AND METHODS FOR THE INTEGRATION OF FRAMING, OAM&P, AND FORWARD ERROR CORRECTION IN SFP OPTICAL TRANSCEIVER DEVICES - The present invention provides systems and methods for integrated framing functionality; optical layer operations, administration, maintenance, and provisioning (OAM&P); forward error correction (FEC); data encapsulation; and performance enhancement support in SFP optical transceiver modules. An SFP pluggable transceiver is configured to frame a client signal and to provide OAM&P functionality, such as with G.709 framing. The SFP pluggable transceiver operates within existing multi-source agreement (MSA) specifications for SFP. Accordingly, the pluggable transceiver can operate in any customer device compliant to the MSA specifications. | 04-23-2009 |
20090317073 | SYSTEMS AND METHODS FOR ETHERNET EXTENSION AND DEMARCATION - The present invention provides Ethernet extension and demarcation functionality through a Multi-Source Agreement (MSA) pluggable transceiver in a customer or remote device. The pluggable transceiver is configured to frame an Ethernet client signal and to provide OAM&P functionality, such as with G.709 framing. The pluggable transceiver operates within existing multi-source agreement (MSA) specifications. Accordingly, the pluggable transceiver can operate in any customer device compliant to the MSA specifications. Additionally, the framing and OAM&P functionality are transparent to the customer device, but instead utilized by a service provider for demarcation functionality, eliminating the requirements for external demarcation equipment and for external transponders. | 12-24-2009 |
20110135312 | 40G/100G OPTICAL TRANSCEIVERS WITH INTEGRATED FRAMING AND FORWARD ERROR CORRECTION - The present disclosure provides integrated performance monitoring (PM); optical layer operations, administration, maintenance, and provisioning (OAM&P); and alarming in optical transceivers, such as multi-source agreement (MSA)-defined modules. The present disclosure includes an optical transceiver defined by an MSA agreement with integrated PM and alarming for carrier-grade operation. The integration preserves the existing MSA specifications allowing the optical transceiver to operate with any compliant MSA host device. Further, the host device can be configured through software to retrieve the PM and alarming from the optical transceiver. The optical transceiver can include CFP and variants thereof (e.g., future CFP2, CDFP, CXP), OIF-MSA-100GLH-EM-01.0, CCRx (Compact Coherent Receiver), Quad Small Form-factor Pluggable (QSFP) and variants thereof (e.g., future QSFP+, QSFP2), 10×10 MSA, XFP, XPAK, XENPAK, X2, XFP-E, SFP, SFP+, 300-pin, and the like. | 06-09-2011 |
20130136445 | OPTICAL TRANSCEIVER PERFORMANCE MONITORING AND ALARMING SYSTEMS AND METHODS - Performance monitoring (PM); optical layer operations, administration, maintenance, and provisioning (OAM&P); and alarming are provided in optical transceivers, such as multi-source agreement (MSA)-defined modules. The present disclosure provides an optical transceiver defined by an MSA agreement with integrated PM and alarming for carrier-grade operation. The integration preserves the existing MSA specifications allowing the optical transceiver to operate with any compliant MSA host device. Further, the host device can be configured through software to retrieve the PM and alarming from the optical transceiver. The optical transceiver can include XFP, XPAK, XENPAK, X2, XFP-E, SFP, SFP+, 300-pin, and the like. The optical transceiver is configured to frame incoming signals to provide overhead and FEC. The transceiver provides access to all alarms in ITU-T G.709, all Tandem Connection Monitoring (TCM) bytes in G.709, far end monitoring as specified in G.709, loopbacks, historical and real-time PM values, and the like. | 05-30-2013 |
20130136446 | VIRTUALIZED OPTICAL TRANSPORT NETWORK SYSTEMS AND METHODS - The present disclosure provides an optical transceiver, method of mapping, and method of management utilizing a plurality of Optical Channel Transport Unit layer k (OTUk) links to form an aggregate signal, such as, for example, 10 OTU2s to provide a single 100 Gigabit Ethernet (100 GbE) signal. Specifically, the present invention enables use of existing circuitry and methods at lower speed signals, e.g. 10 G, to support higher speed aggregate signals, e.g. 100 G. The present invention may be utilized to support carrier-grade OTN applications with optical transceivers such as, for example, pluggable optical transceivers. In an exemplary embodiment, the present invention includes a method which receives a plurality of signals, frames each of the plurality of signals into an OTUk frame, and manages/monitors each of the plurality of signals in an OTUk frame in the aggregate. | 05-30-2013 |
20130177309 | 40G/100G MSA-COMPLIANT OPTICAL TRANSCEIVERS WITH ADVANCED FUNCTIONALITY - Integrated performance monitoring (PM); optical layer operations, administration, maintenance, and provisioning (OAM&P); alarming; amplification, and the like is described in optical transceivers, such as multi-source agreement (MSA)-defined modules. An optical transceiver defined by an MSA agreement can include advanced integrated functions for carrier-grade operation which preserves the existing MSA specifications allowing the optical transceiver to operate with any compliant MSA host device with advanced features and functionality. The optical transceiver can include CFP and variants thereof (e.g., CFP2, CDFP, CXP), OIF-MSA-100GLH-EM-01.0, CCRx (Compact Coherent Receiver), Quad Small Form-factor Pluggable (QSFP) and variants thereof (e.g., QSFP+, QSFP2), 10X10 MSA, XFP, XPAK, XENPAK, X2, XFP-E, SFP, SFP+, 300-pin, and the like. | 07-11-2013 |
Patent application number | Description | Published |
20100239653 | PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING TUMORS - The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof. | 09-23-2010 |